Rafael pharmaceuticals announces published data on cpi-613® (devimistat) from phase 2 clinical trial for refractory burkitt lymphoma at the 2021 american society of hematology (ash) annual meeting and exposition

Published study titled, “complete remission with devimistat (cpi-613) in refractory burkitt lymphoma” published study titled, “complete remission with devimistat (cpi-613) in refractory burkitt lymphoma”
RFL Ratings Summary
RFL Quant Ranking